Current and future development of estrogen receptor ligands: applications in estrogen-related cancers

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• 17β-Estradiol (E2) is a key hormone regulating physiological processes through estrogen receptors (ERs).
• ERs play critical roles in the development and progression of various pathologies, notably hormone-dependent cancers.
• Two mammalian ER subtypes, ERα and ERβ, exhibit distinct tissue distributions and mediate E2's effects via genomic and extranuclear mechanisms.

Purpose of the Study:

• To summarize the complex roles of ER subtypes in E2-dependent cancers.
• To review current drug-targeting strategies for ERs.
• To highlight novel molecules and future directions in anti-ER therapeutic development.

Main Methods:

• Literature review of molecular events in nuclear and extranuclear compartments related to ER function in cancer.
• Analysis of current and emerging drug-targeting strategies for ERs.
• Examination of recent literature and patents on new anti-ER molecules.

Main Results:

• The relative contribution of ERα and ERβ in E2-dependent cancers is complex, involving both nuclear and extranuclear molecular events.
• Several novel molecules targeting ERs have been identified, showing promise for improved anti-hormonal therapies.
• Existing therapeutic strategies can be enhanced by considering the full spectrum of ER biology.

Conclusions:

• Understanding the intricate roles of ER subtypes and their mechanisms is crucial for effective cancer treatment.
• New drug design programs incorporating all ER molecular mechanisms are needed to advance anti-ER therapies.
• Further research and patent exploration will likely yield more potent and targeted anti-hormonal treatments.